Rolf Ehrhardt, the President and CEO of MedCision discusses the key factors to be considered when commercializing a cell therapy to meet patient demand.
Syngeneic mouse models as a tool to study immune modulatory effects of cancer therapeutics
T: +44 (0)20 3141 8700
To be confirmed for 2018| London, UK
© Copyright 2017 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.